马氏竹制药物灸疗法治疗腰椎间盘突出症下腰痛的随机对照试验研究方案
本研究为多中心、随机、平行组、非劣效性试验,计划纳入312例腰椎间盘突出症下腰痛患者,随机分为马氏竹制药物灸组(n=156)与针刺组(n=156),每周治疗6次、共12次,随访至治疗结束后14天,主要结局为视觉模拟量表(VAS),并评估Oswestry功能障碍指数、改良日本骨科协会下腰痛评分、血清β-内啡肽与P物质及安全性。
要点
- 马氏竹制药物灸疗法已广泛用于缓解下腰痛,小样本研究显示疼痛缓解有显著改善。
- 本试验为多中心、随机、平行组、非劣效性设计,比较马氏竹制药物灸与针刺的疗效与安全性。
- 主要结局为基线、治疗6次后、治疗结束时及随访时的VAS评分。
核心结论
- 试验结果将比较马氏竹制药物灸组与针刺组对腰椎间盘突出症下腰痛的疗效,并期望对马氏竹制药物灸疗法的临床疗效与安全性做出系统、客观的评价。
研究设计与样本
- 多中心、随机、平行组、非劣效性研究,计划纳入312例患者,随机分为马氏竹制药物灸组(n=156)与针刺组(n=156)。
- 两组患者每日治疗,每周6次,共12次;治疗结束后14天进行随访。
关键数值与推荐
- 主要结局为基线、治疗6次后、治疗结束时及随访时的视觉模拟量表(VAS)评分。
- 次要结局包括Oswestry功能障碍指数(ODI)、改良日本骨科协会下腰痛(M-JOA)评分、血清β-内啡肽(β-EP)及血清P物质(SP)。
- β-EP、SP及安全性评价指标(血常规、肝肾功能、心电图)于基线和治疗结束时测量。
- 记录不良事件的数量、性质及严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lumbar disc herniation (LDH) is a common and frequently occurring disease in clinics. Low back pain and sciatica are the presenting symptoms of LDH. To some extent, it can be considered that measures with the capability to improve low back pain or sciatica have the potential to treat LDH. Ma's bamboo-based medicinal moxibustion therapy can effectively reduce the degree of low back pain and has been widely used. Studies of small sample size have seen significant improvement on pain relief. The aim of this trial is to evaluate the clinical efficacy and safety of Ma's bamboo-based medicinal moxibustion therapy in the treatment of LDH low back pain. METHODS/DESIGN: The trial is a multicenter, randomized, parallel-group, non-inferiority study. Three hundred and twelve patients will be randomly assigned to a Ma's bamboo-based medicinal moxibustion group (n=156) and an acupuncture group (n=156). Patients in each group will receive treatment every day, 6 times a week, 12 times in total. Follow-up will be conducted 14 days after treatment. The primary outcome will be the visual analog scale(VAS) at baseline, after 6 times of treatment, end of treatment, and follow-up. The secondary outcomes will include Oswestry disability indexes (ODI), modified Japanese Orthopaedic Association low back pain (M-JOA) score, serum β-endorphin (β-EP), and serum substance P (SP). β-EP and SP, as well as safety evaluation indexes (routine blood, liver, and kidney function and electrocardiogram), will be measure at baseline and after the end of treatment. The number, nature, and severity of adverse events will be recorded. DISCUSSION: The results of the trial will compare the efficacy of low back pain in LDH between Ma's bamboo-based medicinal moxibustion group and the acupuncture group and will be expected to make a systematic and objective evaluation of the clinical efficacy and safety of Ma's bamboo-based medicinal moxibustion therapy. TRIAL REGISTRATION: ChiCTR2000038725 . Registered on 29 September 2020.
引用
- Wang XZ, Xue KY, Chen PN, et al. Ma's bamboo-based medicinal moxibustion therapy of low back pain in lumbar disc herniation: study protocol for a randomized controlled trial. Trials. 2022. PMID: 35643520. doi:10.1186/s13063-022-06382-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。